Thermal Pulsation for MGD

Thermal pulsation is an in-office treatment designed primarily for meibomian gland dysfunction. Instead of heating the outside of the closed eyelid with a warm compress, a device applies controlled heat and mechanical pressure in a standardized way.

With LipiFlow, a single-use applicator is positioned around the eyelids. The system heats the inner eyelid surface while simultaneously applying pulsating pressure to the outer eyelid. A standard LipiFlow treatment lasts approximately 12 minutes. The purpose is to make poorly flowing meibum more fluid while mechanically helping move it through the gland ducts.

Remember the problem we discussed with warm compresses. If heat is applied to the outside of the eyelid, it has to travel through the eyelid tissue before reaching the meibomian glands. Some heat is lost. Thermal pulsation systems were designed partly to solve this problem by delivering controlled heat closer to the glands. At the same time, the system protects the ocular surface while the eyelid is being heated.

The theoretical advantage is therefore not simply more heat. It is more controlled delivery of heat to the target tissue.

Because making meibum more fluid does not necessarily make it leave an obstructed gland. If the secretion remains trapped inside the gland, mechanical force may help evacuate it. So thermal pulsation combines:

thermal treatment: change meibum fluidity→mechanical treatment: facilitate gland evacuation

That is the fundamental treatment concept.

Conceptually, yes. But there are differences. With a home warm compress, temperature can vary substantially. With manual gland expression, the amount of pressure depends on the clinician and can vary from one part of the eyelid to another. Thermal pulsation attempts to standardize both. The device controls:

• •temperature
• •treatment duration
• •pressure
• •pressure pattern

That makes the procedure more reproducible than “warm the eyelids somehow and then manually squeeze them.” But better standardization does not automatically prove better clinical outcomes. That question requires trials.

There is evidence that it can improve meibomian gland function and some dry-eye outcomes. The American Academy of Ophthalmology reviewed 11 studies of LipiFlow and concluded that a single thermal pulsation treatment may safely improve subjective or objective measures of MGD and dry eye, with improvements reported from one month to one year after treatment. TFOS DEWS III also includes device-based eyelid heating among contemporary in-office approaches to MGD management.

So thermal pulsation is not an experimental treatment with no clinical evidence. But the next question is more interesting.

This is much less clear. A 2024 Cochrane review included 13 randomized trials involving 1,155 participants. Five trials directly compared LipiFlow with basic warm compresses. The evidence for symptom improvement was conflicting. And importantly, the review found no evidence of a difference between LipiFlow and basic warm compresses in meibomian gland expression, meibum quality or tear break-up time. Overall, the certainty of evidence was considered low or very low, and many trials had a high risk of bias.

This does not mean that LipiFlow doesn’t work. It means that we do not have strong evidence that LipiFlow consistently outperforms simpler treatments. Those are very different conclusions.

Yes — some have. This is one reason the literature can look confusing. In the American Academy of Ophthalmology review, 9 of 11 studies reported greater efficacy for thermal pulsation than standard warm compresses and lid hygiene. But four of those studies had relevant industry conflicts of interest. And among four higher-level studies without direct industry participation, two concluded that thermal pulsation was not significantly different from conventional warm-compress or lid-hygiene treatment for the relevant outcomes.

That doesn’t invalidate industry-funded research. But funding and study design are relevant when we assess the overall strength of an evidence base.

A 2025 systematic review and meta-analysis of randomized trials found an interesting pattern. LipiFlow significantly improved a measure of meibomian gland secretion function (MGYSS) compared with controls. It also found a small improvement in corneal staining. But pooled differences in the following were not statistically significant:

• •OSDI symptoms
• •tear break-up time
• •lipid-layer thickness

This is actually a very useful result. A treatment can produce a measurable improvement in the biological target — gland secretion — without producing an equally large or consistent improvement in every downstream dry-eye measurement.

Because symptoms do not come from the meibomian glands alone. Suppose thermal pulsation successfully improves gland secretion. But the patient also has:

• •aqueous deficiency
• •ocular-surface inflammation
• •incomplete blinking
• •exposure
• •or persistent neural sensitization

The glands may objectively improve while symptoms remain. That does not necessarily mean the thermal pulsation failed. It may mean that MGD was not the only driver of the symptoms. This is exactly why we started the treatment section with “Start With the Target.”

Treating Dry Eye: Start With the Target

Dry Eye Is Often Mixed

Thermal pulsation makes the most biological sense when there is a problem it can actually address: functioning meibomian glands and poorly flowing or obstructed secretion. In other words, there needs to be something worth heating and evacuating. If someone has structurally preserved glands containing thick, poorly expressible meibum, the treatment has an obvious target.

The 2025 meta-analysis found that people with more severe baseline MGD appeared to derive greater benefit in some analyses. But patient-selection evidence is still developing.

This changes the question. Thermal pulsation cannot heat and evacuate a gland that is no longer present. It may potentially improve the function of the remaining glands, but it cannot replace lost glandular tissue. So severe dropout does not necessarily mean that thermal pulsation is useless. But expectations should depend on how much functioning gland tissue remains. Again: structure matters, but function matters too.

Meibography: what gland images can and can't tell you

There is no established evidence that thermal pulsation regenerates truly lost meibomian gland tissue. Claims about gland “regrowth” should therefore be treated cautiously. An apparent improvement in a meibography image does not automatically prove biological regeneration. Thermal pulsation is designed to improve function and outflow in existing glands, not to create new glands.

One unusual feature of LipiFlow research is that many trials evaluate a single 12-minute treatment. The American Academy of Ophthalmology review found reported improvements lasting from approximately one month to one year after one treatment in some studies.

That does not mean every patient receives one treatment and remains improved for a year. Individual response varies. And the duration of benefit is not equally established across all patients and outcomes.

At first this may seem strange. A warm compress changes meibum fluidity temporarily. So why would one thermal treatment potentially produce a longer effect?

The proposed explanation is that thermal pulsation is not simply warming the tear film for a few minutes. If obstructive material is evacuated and gland outflow improves, the gland may temporarily return to more effective secretion. In other words, the hoped-for result is: remove an important functional obstruction, then allow the gland to function more normally afterward.

But the underlying tendency toward MGD may still remain. So improvement does not necessarily mean the underlying condition has been permanently eliminated.

No universal evidence-based schedule exists. You may encounter recommendations such as repeating thermal pulsation every six months or every year. But there is no established rule that every patient with MGD requires treatment on a fixed calendar indefinitely. A more rational question is: has the original target returned?

• •Are glands becoming poorly expressible again?
• •Has meibum quality deteriorated?
• •Has tear-film stability changed?
• •Have symptoms returned alongside objective evidence of recurrent gland dysfunction?

If not, repeating treatment simply because a certain number of months has passed is difficult to justify biologically.

The treatment is designed to use controlled heat and pressure and is generally reported as tolerable. This is potentially important when compared with forceful manual gland expression, where the pressure required to evacuate severely obstructed glands can be painful. The device attempts to deliver pressure in a controlled, standardized pattern rather than relying on intense focal manual squeezing.

However, comfort varies between individuals. Pressure, warmth or temporary discomfort may still occur.

Published trials have generally reported a favorable safety profile. The American Academy of Ophthalmology review found no serious adverse events in the 11 studies it evaluated. The Cochrane review similarly found no intervention-related vision-threatening adverse events in the included trials. That is reassuring.

But as always, the absence of serious events in trials does not mean every person is an appropriate candidate. Clinical assessment and device-specific contraindications still matter.

No. LipiFlow is the best-known and most extensively studied system, but it is not the only device-based treatment using controlled heat and/or mechanical gland evacuation. Other technologies include systems such as iLux and TearCare, although these devices do not deliver treatment in exactly the same way.

That matters scientifically. We should not automatically take evidence from LipiFlow and apply it to every device that heats the eyelids. Different technologies can use different:

• •temperatures
• •heating locations
• •treatment durations
• •methods of gland evacuation

So “thermal treatment” is a category, not one identical procedure.

Radiofrequency (RF) for MGD and Dry Eye: another energy-based approach

Not necessarily. A sophisticated device may offer more controlled temperature, more standardized pressure, and a treatment that does not depend on daily adherence. Those are real practical advantages. But clinical superiority still needs to be demonstrated.

The Cochrane review’s overall conclusion was that LipiFlow appears to perform similarly to other available dry-eye treatments, while better-quality research is still needed. So we should separate technological sophistication from proven additional clinical benefit. They are not the same thing.

This becomes relevant because thermal pulsation is usually considerably more expensive than home warming. If two treatments produce similar outcomes for a particular patient, cost matters. On the other hand, daily warm compresses require:

• •time
• •consistency
• •correct technique
• •long-term adherence

A single in-office treatment may therefore have practical value even if its biological effect is not dramatically superior. So the decision is not purely which one produces the highest number in a clinical trial. It can also involve burden, convenience, adherence, cost and patient preference.

We still cannot answer this directly. A 2025 systematic review examined randomized trials involving both treatments. But critically, none of the 12 included studies directly compared LipiFlow with IPL. Any comparison therefore had to be made indirectly across different studies using different control groups.

So we should not turn those indirect comparisons into “IPL wins” or “LipiFlow wins.” They also do not necessarily target exactly the same biological problem. IPL may have vascular and inflammatory effects in addition to effects on gland function. Thermal pulsation is much more directly aimed at heating meibum and mechanically facilitating gland outflow. The appropriate choice may therefore depend on what is actually wrong.

IPL for Dry Eye and MGD

Again, start with the target. Was there actually obstructive MGD? Did gland secretion improve? How much viable gland tissue was present? Was MGD the main cause of the patient’s symptoms? Were other contributors present? A patient might experience little symptom improvement because the glands did not respond, or because the glands improved but they were not the main reason the eyes hurt. Those are very different treatment failures.

How to Choose a Dry Eye Treatment

Ideally, not only by asking “Do your eyes feel better?” Symptoms matter enormously. But because thermal pulsation has a specific biological target, we can also ask:

• •Has gland expressibility improved?
• •Has meibum quality improved?
• •Are more glands yielding secretion?
• •Is less pressure required?
• •Has tear-film stability changed?
• •Has ocular-surface staining changed?
• •Has the patient become more functional in everyday life?

This allows us to distinguish between “the treatment changed its intended target but symptoms persisted” and “the treatment did not meaningfully change the target at all.”